Skip to content
The method12 hallmarks
Therapies Hyperbaric oxygen therapyBioidentical hormone therapyPEMF therapyFunctional nutritionRegenerative medicinePeptide therapyProtocol 360 Before treatment Initial evaluationAdvanced diagnostics and patient mapping See all therapies
Medical teamThe clinicYour tripContact Español Patient intake

Home / Research note

Research note · November 17, 2026

Hormone therapy and migraine: what the Women's Health Initiative trial found

A new analysis of the Women's Health Initiative trials, with 22,876 women, found that estrogen alone did not worsen headaches, with or without a migraine history. Estrogen combined with progestin was associated with headaches worsening over time, especially in women with a prior migraine history.

What was studied

The Women's Health Initiative (WHI) is one of the largest randomized trials ever run on menopausal hormone therapy. Between 1993 and 1998, 22,876 women in the United States, with an average age of 64, were enrolled in two parallel placebo-controlled trials: one with estrogen alone, for women without a uterus, and one with estrogen plus progestin.

This analysis, published online in July 2026, revisited that data with a different question than the original one: what happens to each woman’s self-reported headache severity, from baseline to one year of follow-up, with and without a migraine history. Ten percent of participants had a lifetime migraine diagnosis.

What it found

Among women with a migraine history, estrogen alone was not associated with more severe headache at one year (adjusted odds ratio of 1.14) or with headaches worsening over time (adjusted risk ratio of 0.98). Estrogen plus progestin was associated with headaches worsening over time (adjusted risk ratio of 1.53), although the increase in headache severity itself did not reach statistical significance.

Among women without a migraine history, the pattern repeated on a smaller scale: estrogen alone showed no strong association, and estrogen plus progestin was modestly associated with moderate-to-severe headache and with headaches worsening over time.

What it means for you

If you have migraine and are on hormone therapy, or considering it, this is useful information for the conversation with your physician: in this trial, adding progestin was linked to a worse headache course, while estrogen alone was not.

The authors sum it up this way: types of hormone therapy differ in how they relate to headache. In this trial, the difference was whether progestin was added.

What it does not say

The estrogen and progestin used in this trial were conjugated equine estrogens and medroxyprogesterone acetate, both oral: a different formula, by molecule, from hormones structurally identical to the body’s own, the kind the clinic’s page describes. The result does not carry over directly to that other formula, though it is reasonable to ask about it in your evaluation.

Participants enrolled between 1993 and 1998, with an average age of 64: older than the age at which the North American Menopause Society considers the balance of starting it most favorable (before 60 or within 10 years of menopause). Headache and migraine history were self-reported, and the analysis was secondary, not the question the original trial was designed to answer. The authors themselves call for more research on newer hormone therapy formulations.

How it connects to BMC

At BMC, hormone therapy is started on a full hormone panel, never on the symptom alone, and with molecules structurally identical to the ones the body produces. If you have a migraine history, say so in your evaluation: it is exactly the kind of history that, per this trial, is worth weighing when choosing the formula.

The source

Original abstract read on October 3, 2026.

Crowe HM, et al. Menopausal Hormone Therapy, Migraine History, and Headache Severity: Results From the Women's Health Initiative Hormone Therapy Clinical Trials. Headache. 2026 Sep (published online 2026 Jul 8).

PubMed 42419355 →

The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022. PubMed 35797481 →

Bioidentical hormone therapy

Does this apply to you?

A study says what happens on average. What makes sense for you comes out of the evaluation, with your history and your lab work.